Ying Wang

Leads the Small Molecule Chemistry Technology (SMCT) group. SMCT is responsible for the development and implementation of chemistry and analytical technologies to facilitate drug discovery research. This includes capabilities such as parallel library synthesis, High-Throughput Experimentation (HTE), analytical sciences, NMR, high-pressure lab operations, biocatalysis, digital chemistry, and other enabling technologies.

 Led Advanced Chemistry Technologies (ACT) group since 2014, an industry leading chemistry technology group specializes in automated parallel library synthesis, high throughput experimentation (HTE), Late -Stage Functionalization (LSF), and a suite of enabling chemistry technologies (photoredox, flow, biocatalysis, and high pressure chemistry) for med chem research.  Built Late-Stage Functionalization (LSF) capability for lead compound diversification at AbbVie  Initiated and established HTE function within AbbVie Discovery by leveraging proprietary ChemBeads technology (co-inventor) in 2017.  Championed the first wave of machine learning (ML) in chemistry projects (2019); proposed and chaired cross-function ML in Chemistry working group; advocated and pioneered the work on the integration of ML on med chem research utilizing internal chemistry data sets.  Led the efforts and set strategies on enhancing corporate building block collection accessibility, searchability, and synthesis; Chair of the Strategic Monomer initiative at AbbVie and AbbVie representative on precompetitive BBXC (Building Block Exchange Consortium).

 Managed a 6-year multi-million Corporate File Enhancement Initiative; Executed 25 outsourcing projects, which resulted in the addition of 100,000+ proprietary compounds to corporate compound collection.  7+year drug discovery experience in directing medicinal chemistry efforts on multiple neuroscience and oncology projects.  Spearheaded several strategic initiatives/collaborations including the investigation of thermodynamic and kinetic profiling in drug discovery and the development of software/ websites/ database to facilitate med chem research.

 Designed and implemented the efficient total synthesis of Leucascandrolide A, a highly bioactive marine macrolide in 18 linear steps.  Created and patented a conceptually novel three dimensional array method for the multiparallel synthesis and successfully applied this concept to small molecule library synthesis.

 Discovered, characterized and published a highly efficient catalytic system for deprotection of pyridine N-oxides to pyridines.  Discovered and studied a general and efficient catalytic system for diverse oxygen transfer reactions.